Macrolide resistance in Streptococcus pneumoniae: Fallacy or fact?
作者信息
Conly Jm, Johnston Bl
机构信息
Departments of Pathology and Laboratory Medicine, Medicine, and Microbiology & Infectious Diseases, University of Calgary, Calgary, Alberta;
出版信息
Can J Infect Dis. 2002 Jan;13(1):13-6. doi: 10.1155/2002/501543.
Abstract
摘要
相似文献
1
Macrolide resistance in Streptococcus pneumoniae: Fallacy or fact?肺炎链球菌对大环内酯类药物的耐药性：谬误还是事实？
Can J Infect Dis. 2002 Jan;13(1):13-6. doi: 10.1155/2002/501543.
2
Molecular characterization of macrolide resistance mechanisms among Streptococcus pneumoniae and Streptococcus pyogenes isolated from the PROTEKT 1999-2000 study.从1999 - 2000年PROTEKT研究中分离出的肺炎链球菌和化脓性链球菌大环内酯类耐药机制的分子特征
J Antimicrob Chemother. 2002 Sep;50 Suppl S1:39-47. doi: 10.1093/jac/dkf806.
3
Identification and prioritization of macrolideresistance genes with hypothetical annotation inStreptococcus pneumoniae.肺炎链球菌中具有假设注释的大环内酯抗性基因的鉴定与优先级排序
Bioinformation. 2018 Dec 9;14(9):488-498. doi: 10.6026/97320630014488. eCollection 2018.
4
Increase of Macrolide-Resistance in Strains After the Introduction of the 13-Valent Pneumococcal Conjugate Vaccine in Lima, Peru.秘鲁利马引入 13 价肺炎球菌结合疫苗后，菌株中大环内酯类耐药性增加。
Front Cell Infect Microbiol. 2022 May 9;12:866186. doi: 10.3389/fcimb.2022.866186. eCollection 2022.
5
Macrolide Resistance in .……中的大环内酯类耐药性
Front Cell Infect Microbiol. 2016 Sep 21;6:98. doi: 10.3389/fcimb.2016.00098. eCollection 2016.
6
Macrolide resistance mechanisms among Streptococcus pneumoniae isolated over 6 years of Canadian Respiratory Organism Susceptibility Study (CROSS) (1998 2004).在加拿大呼吸道病原体药敏试验（CROSS，1998 - 2004年）的6年期间分离出的肺炎链球菌中的大环内酯类耐药机制。
J Antimicrob Chemother. 2007 Oct;60(4):733-40. doi: 10.1093/jac/dkm273. Epub 2007 Aug 2.
7
Is There a Resistance Threshold for Macrolide Consumption? Positive Evidence from an Ecological Analysis of Resistance Data from , and .大环内酯类药物使用是否存在耐药阈值？来自[具体地区1]、[具体地区2]和[具体地区3]耐药数据的生态学分析的肯定证据。
Microb Drug Resist. 2021 Aug;27(8):1079-1086. doi: 10.1089/mdr.2020.0490. Epub 2021 Feb 16.
8
Pharmacodynamic activity of azithromycin against macrolide-susceptible and -resistant Streptococcus pneumoniae simulating clinically achievable free serum, epithelial lining fluid and middle ear fluid concentrations.阿奇霉素对大环内酯类敏感和耐药肺炎链球菌的药效学活性，模拟临床可达到的游离血清、上皮衬液和中耳液浓度。
J Antimicrob Chemother. 2003 Jul;52(1):83-8. doi: 10.1093/jac/dkg278. Epub 2003 May 29.
9
Correlation between usage of macrolide antibiotic and resistance of Streptococcus pneumoniae clinic isolates from Chongqing children's hospital.重庆儿童医院肺炎链球菌临床分离株大环内酯类抗生素使用情况与耐药性的相关性
Pediatr Pulmonol. 2009 Sep;44(9):917-21. doi: 10.1002/ppul.21081.
10
Distribution across the USA of macrolide resistance and macrolide resistance mechanisms among Streptococcus pneumoniae isolates collected from patients with respiratory tract infections: PROTEKT US 2001-2002.从呼吸道感染患者中分离出的肺炎链球菌菌株对大环内酯类药物的耐药性及耐药机制在美国的分布情况：2001 - 2002年美国肺炎链球菌耐药性监测研究（PROTEKT US）
J Antimicrob Chemother. 2004 Aug;54 Suppl 1:i17-22. doi: 10.1093/jac/dkh312.
本文引用的文献
1
Macrolide resistance among invasive Streptococcus pneumoniae isolates.侵袭性肺炎链球菌分离株中的大环内酯类耐药性
JAMA. 2001 Oct 17;286(15):1857-62. doi: 10.1001/jama.286.15.1857.
2
The hidden impact of antibacterial resistance in respiratory tract infection. Clinical failures: the tip of the iceberg?
Respir Med. 2001 Jun;95 Suppl A:S5-11; discussion S26-7. doi: 10.1016/s0954-6111(01)90022-8.
3
Macrolide-resistant Streptococcus pneumoniae in Canada during 1998-1999: prevalence of mef(A) and erm(B) and susceptibilities to ketolides.1998 - 1999年加拿大耐大环内酯类肺炎链球菌：mef(A)和erm(B)的流行情况以及对酮内酯类的敏感性
Antimicrob Agents Chemother. 2001 Jul;45(7):2147-50. doi: 10.1128/AAC.45.7.2147-2150.2001.
4
In vitro activity and pharmacodynamics of azithromycin and clarithromycin against Streptococcus pneumoniae based on serum and intrapulmonary pharmacokinetics.基于血清和肺内药代动力学的阿奇霉素和克拉霉素对肺炎链球菌的体外活性及药效学研究
Clin Ther. 2001 Mar;23(3):413-24. doi: 10.1016/s0149-2918(01)80046-1.
5
Increasing prevalence of multidrug-resistant Streptococcus pneumoniae in the United States.美国多重耐药肺炎链球菌的患病率不断上升。
N Engl J Med. 2000 Dec 28;343(26):1917-24. doi: 10.1056/NEJM200012283432603.
6
Fatal pneumococcal pneumonia attributed to macrolide resistance and azithromycin monotherapy.归因于大环内酯类耐药和阿奇霉素单药治疗的致命性肺炎球菌肺炎
Chest. 2000 Dec;118(6):1839-40. doi: 10.1378/chest.118.6.1839-a.
7
Two new mechanisms of macrolide resistance in clinical strains of Streptococcus pneumoniae from Eastern Europe and North America.来自东欧和北美的肺炎链球菌临床菌株中两种新的大环内酯类耐药机制。
Antimicrob Agents Chemother. 2000 Dec;44(12):3395-401. doi: 10.1128/AAC.44.12.3395-3401.2000.
8
Breakthrough pneumococcal bacteremia in patients being treated with azithromycin and clarithromycin.接受阿奇霉素和克拉霉素治疗的患者出现突破性肺炎球菌菌血症。
Clin Infect Dis. 2000 Oct;31(4):1008-11. doi: 10.1086/318157. Epub 2000 Oct 13.
9
Limiting the spread of resistant pneumococci: biological and epidemiologic evidence for the effectiveness of alternative interventions.限制耐药肺炎球菌的传播：替代干预措施有效性的生物学和流行病学证据
Clin Microbiol Rev. 2000 Oct;13(4):588-601. doi: 10.1128/CMR.13.4.588.
10
Bacteremic pneumonia due to multidrug-resistant pneumococci in 3 patients treated unsuccessfully with azithromycin and successfully with levofloxacin.3例耐多药肺炎球菌所致菌血症性肺炎患者，使用阿奇霉素治疗失败，而使用左氧氟沙星治疗成功。
Clin Infect Dis. 2000 Aug;31(2):613-5. doi: 10.1086/313976.
Zotero 插件